The recent surge in investments into boutique pharmaceutical companies, particularly those focusing on groundbreaking therapies and challenging drug development programs, has fueled what some are calling "High Investor Pharma." While the promise for game-changing treatments and impressive returns is certain, the linked risks are also considerable.